Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02196896
Recruitment Status : Completed
First Posted : July 22, 2014
Last Update Posted : March 17, 2017
Sponsor:
Collaborator:
Rhön-Klinikum AG
Information provided by (Responsible Party):
M.E. Beutel, Johannes Gutenberg University Mainz

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine the acceptance and efficacy of the online self-help program deprexis® for depressed patients in reducing the clinical symptoms of their depression. The patients of the experimental group use deprexis® for 90 days, the patients of the placebo group receive weekly online information about depression for 90 days as well. Both groups receive their treatment in addition to their regular inpatient psychosomatic treatment and as an aftercare intervention.The investigators hypothesize that the online self-help group achieves a greater reduction of depression compared to the control group.

Condition or disease Intervention/treatment Phase
Depression Other: deprexis® Other: Information Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 229 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Enhancing Inpatient Psychotherapeutic Treatment With Online Self Help in a Randomised Controlled Trial: Acceptance and Efficacy
Study Start Date : June 2014
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: deprexis®
Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
 Other: deprexis®
Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
Placebo Comparator: Information
Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
 Other: Information
The patients receive online information about depression once a week for 90 days.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Reduction of depression measured with the "Beck's Depression Inventory" (BDI-II) [ Time Frame: Three months after randomization ]

Secondary Outcome Measures :
  1. Reduction of depression measured with the depression scale of the "Patient Health Questionnaire" (PHQ-9) [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks), six months after randomization ]
  2. Reduction of depression measured with the "Beck's Depression Inventory" (BDI-II) [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks), six months after randomization ]
  3. Reduction of anxiety measured with the "Generalized Anxiety Disorder Scale" (GAD-7) [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks), six months after randomization ]
  4. Reduction of dysfunctional depression related cognitions measured with the "Dysfunctional Attitude Scale" (DAS) [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks), six months after randomization ]
  5. Improved self-esteem measured with the "Rosenberg Self-Esteem Scale" (RSE) [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks), six months after randomization ]
  6. Improved quality of life measured with the "European Health Interview Survey Quality of Life-8" (EUROHIS-QOL 8) [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks), six months after randomization ]
  7. Improved working ability measured with the short form of the "Work Ability Index" (WAI) [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks), six months after randomization ]
  8. Acceptance and utilization of deprexis® measured with a self devised questionnaire [ Time Frame: End of inpatient treatment (average 6 weeks), three months after randomization ]
  9. Acceptance and utilization of the information used in the placebo condition measured with a self devised questionnaire [ Time Frame: End of inpatient treatment (average 6 weeks), three months after randomization ]
  10. Degree of childhood traumas measured with the "Childhood Trauma Questionnaire" (CTQ) [ Time Frame: Randomization ]
    Assumption that childhood traumas, assessed at the beginning of treatment, have a moderating effect on the reduction in the primary outcome measure.

  11. Degree of structural deficits measured with the short form of the OPD-Structure Questionnaire (OPD-SFK) [ Time Frame: Randomization ]
    Assumption that structural deficits, as assessed with the OPD-SFK questionnaire at the beginning of treatment have a moderating effect on the reduction in the primary outcome measure.

  12. Therapeutic alliance between participant and inpatient psychotherapist measured with the "Helping Alliance Questionnaire" (HAQ). [ Time Frame: Randomization, end of inpatient treatment (average 6 weeks) ]
  13. Course of mood, depressiveness and utilization of units [ Time Frame: During inpatient treatment (average 6 weeks) ]
  14. Utilization of other treatments after the end of inpatient treatment [ Time Frame: Six months after randomization ]
  15. Satisfaction with inpatient treatment [ Time Frame: End of inpatient treatment (average 6 weeks) ]
  16. Willingness to pay [ Time Frame: Three months after randomization ]
  17. Remission from depression [ Time Frame: End of inpatient treatment (average 6 weeks), three months after randomization, six months after randomization ]
    BDI score below the cutoff of 13 and a reliable change regarding Reliable Change Index (RCI)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Inpatient treatment
  • Private internet access
  • Informed consent
  • Age between 18 and 65 years
  • Knowledge of the German language
  • Score in the BDI-II > 13 and clinical diagnosis of a depression (ICD-10: F32.x, F33.x, F34.1, F43.2) verified by the inpatient therapist

Exclusion Criteria:

  • Psychosis
  • Current alcohol or drug dependency
  • Borderline, antisocial, schizoid or schizotypal personality disorder
  • Anorexia nervosa
  • Life time diagnosis of a schizophrenia, schizoaffective , bipolar oder organic psychic disorder
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02196896


Locations
Layout table for location information
Germany
Psychosomatic Clinic Bad Neustadt
Bad Neustadt, Bavaria, Germany, 97616
University Medical Center, Department of Psychosomatic Medicine and Psychotherapy, Johannes Gutenberg University
Mainz, Rhineland-Palatinate, Germany, 55131
Sponsors and Collaborators
Johannes Gutenberg University Mainz
Rhön-Klinikum AG
Investigators
Layout table for investigator information
Principal Investigator: Manfred E Beutel, Prof. Dr. University Medical Center, Department of Psychosomatic Medicine and Psychotherapy, Johannes Gutenberg University Mainz
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: M.E. Beutel, Prof. Dr., Johannes Gutenberg University Mainz
ClinicalTrials.gov Identifier: NCT02196896     History of Changes
Other Study ID Numbers: RK-97880
First Posted: July 22, 2014    Key Record Dates
Last Update Posted: March 17, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Behavioral Symptoms
Psychotropic Drugs